Status:
UNKNOWN
Squid Liquid Embolic Agent for the Embolization of Abdominopelvic Arterial Bleeding Syndrome (SQUIDperi Study)
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Arterial Bleed
Abdominal
Eligibility:
All Genders
18+ years
Brief Summary
Abdominopelvic bleeding can occur due to numerous causes including for the vast majority, trauma, surgery complications and tumors. Interventional radiologists often exclude arterial acute hemorrhage ...
Eligibility Criteria
Inclusion
- Patient presenting with an arterial abdominopelvic bleeding or imminent risk of bleeding, including visceral, muscular or GI territories, requiring embolization, along with angiographic abnormalities
- Patient for whom the use of SQUIDperi had been decided for an embolization
- Patient or authorized representative dully informed and having no objection to the clinical data collection and medical file access
- Patient \> 18 years
Exclusion
- Patient with severe live failure
- Patient participating in another interventional study
- Vulnerable patients including pregnant women
- Patient not eligible for treatment with liquid embolic agent
- Patients presenting contra-indications to SQUIDperi as describes in the Informations For Use (IFU)
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04787120
Start Date
April 1 2021
End Date
March 1 2024
Last Update
March 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Dijon Bourgogne
Dijon, France, 21000